OBJECTIVE: Hereditary haemorrhagic telangiectasia (HHT) is a genetic disorder related to mutations in one of the coreceptors to the transforming growth factor-β superfamily (ALK1 or endoglin). Besides the obvious vascular symptoms (epistaxis and arteriovenous malformations), patients have an unexplained high risk of severe bacterial infections. The aim of the study was to assess the main immunological functions of patients with HHT using the standard biological tests for primary immunodeficiencies. DESIGN, SETTING AND SUBJECTS: A prospective single-centre study of 42 consecutive adult patients with an established diagnosis of HHT was conducted at the National French HHT Reference Center (Lyon). Lymphocyte subpopulations and proliferation capacity, immunoglobulin levels and neutrophil and monocyte phagocytosis, oxidative burst and chemotaxis were assessed. RESULTS: Innate immunity was not altered in patients with HHT. With regard to adaptive immunity, significant changes were seen in immunological parameters: primarily, a lymphopenia in patients with HHT compared with healthy control subjects affecting mean CD4 (642 cells μL(-1) vs. 832 cells μL(-1) , P < 0.001), CD8 (295 cells μL(-1) vs. 501 cells μL(-1) , P < 0.0001) and natural killer (NK) cells (169 cells μL(-1) vs. 221 cells μL(-1) , P < 0.01), associated with increased levels of immunoglobulins G and A. This lymphopenia mainly concerned naïve T cells. Proliferation capacities of lymphocytes were normal. Lymphopenic patients had a higher frequency of iron supplementation but no increase in infection rate. Lower levels of immunoglobulin M and a higher rate of pulmonary arteriovenous malformations were found amongst patients with a history of severe infection. CONCLUSIONS: Patients with HHT exhibit immunological abnormalities including T CD4, T CD8 and NK cell lymphopenia and increased levels of immunoglobulins G and A. The observed low level of immunoglobulin M requires further investigation to determine whether it is a specific risk factor for infection in HHT.
OBJECTIVE:Hereditary haemorrhagic telangiectasia (HHT) is a genetic disorder related to mutations in one of the coreceptors to the transforming growth factor-β superfamily (ALK1 or endoglin). Besides the obvious vascular symptoms (epistaxis and arteriovenous malformations), patients have an unexplained high risk of severe bacterial infections. The aim of the study was to assess the main immunological functions of patients with HHT using the standard biological tests for primary immunodeficiencies. DESIGN, SETTING AND SUBJECTS: A prospective single-centre study of 42 consecutive adult patients with an established diagnosis of HHT was conducted at the National French HHT Reference Center (Lyon). Lymphocyte subpopulations and proliferation capacity, immunoglobulin levels and neutrophil and monocyte phagocytosis, oxidative burst and chemotaxis were assessed. RESULTS: Innate immunity was not altered in patients with HHT. With regard to adaptive immunity, significant changes were seen in immunological parameters: primarily, a lymphopenia in patients with HHT compared with healthy control subjects affecting mean CD4 (642 cells μL(-1) vs. 832 cells μL(-1) , P < 0.001), CD8 (295 cells μL(-1) vs. 501 cells μL(-1) , P < 0.0001) and natural killer (NK) cells (169 cells μL(-1) vs. 221 cells μL(-1) , P < 0.01), associated with increased levels of immunoglobulins G and A. This lymphopenia mainly concerned naïve T cells. Proliferation capacities of lymphocytes were normal. Lymphopenicpatients had a higher frequency of iron supplementation but no increase in infection rate. Lower levels of immunoglobulin M and a higher rate of pulmonary arteriovenous malformations were found amongst patients with a history of severe infection. CONCLUSIONS:Patients with HHT exhibit immunological abnormalities including T CD4, T CD8 and NK cell lymphopenia and increased levels of immunoglobulins G and A. The observed low level of immunoglobulin M requires further investigation to determine whether it is a specific risk factor for infection in HHT.
Authors: Anthony Cannavicci; Qiuwang Zhang; Si-Cheng Dai; Marie E Faughnan; Michael J B Kutryk Journal: Can J Physiol Pharmacol Date: 2018-12-04 Impact factor: 2.273
Authors: Juan Rodríguez-García; Roberto Zarrabeitia-Puente; Rafael Fernández-Santos; José Antonio García-Erce Journal: Haematologica Date: 2018-10 Impact factor: 9.941
Authors: Vincent Q Sier; Joost R van der Vorst; Paul H A Quax; Margreet R de Vries; Elham Zonoobi; Alexander L Vahrmeijer; Ilona A Dekkers; Lioe-Fee de Geus-Oei; Anke M Smits; Weibo Cai; Cornelis F M Sier; Marie José T H Goumans; Lukas J A C Hawinkels Journal: Int J Mol Sci Date: 2021-04-30 Impact factor: 5.923
Authors: Luisa Ojeda-Fernández; Lucía Recio-Poveda; Mikel Aristorena; Pedro Lastres; Francisco J Blanco; Francisco Sanz-Rodríguez; Eunate Gallardo-Vara; Mateo de las Casas-Engel; Ángel Corbí; Helen M Arthur; Carmelo Bernabeu; Luisa M Botella Journal: PLoS Genet Date: 2016-03-24 Impact factor: 5.917
Authors: Calinda K E Dingenouts; Wineke Bakker; Kirsten Lodder; Karien C Wiesmeijer; Asja T Moerkamp; Janita A Maring; Helen M Arthur; Anke M Smits; Marie-José Goumans Journal: PLoS One Date: 2017-12-18 Impact factor: 3.240
Authors: Roman Wójcik; Joanna Małaczewska; Grzegorz Zwierzchowski; Jan Miciński; Edyta Kaczorek-Łukowska Journal: BMC Vet Res Date: 2020-06-01 Impact factor: 2.741